MarketCapExport financials
Atossa Therapeutics (ATOS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Atossa Therapeutics Financial Ratios 2025-2009 | ATOS
Brief overview of Atossa Therapeutics's financial ratios
The comparison uses the five latest available annual observations between 2019 and 2024.
Market valuation is represented by EV/EBITDA 0.75x (median 0.75x), P/B 1.19x (median 1.16x). On average, multiples differ from their five-year medians by only +1.1%. Valuation is near its familiar historical range.
The latest available business-quality ratios are ROE -88.4%, ROA -73%, ROCE -94.4%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Price, earnings and growth produce a PEG of 0.45x. A value below one indicates moderate pricing relative to expected growth.
Overall picture
Atossa Therapeutics trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Atossa Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.3 | -1.8 | -8.4 | -3.2 | -7.8 | -1.3 | -0.7 | -0.5 | -0.8 | -0.5 | -0.5 | -1.9 | -3.7 | -11.5 | - | - | - |
P/S |
- | - | - | - | - | - | - | - | - | - | 4204.3 | 53.5 | 62.7 | 121.7 | - | - | - |
EPS |
-4.0 | -3.0 | -0.2 | -0.2 | -0.2 | -2.0 | -2.0 | -5.5 | -11.0 | -2.2 | -8.3 | -0.6 | -0.7 | -0.4 | -0.4 | - | - |
EV (Enterprise Value) |
13.6 M | -20.6 M | 169 M | -19.2 M | 27 M | -1.42 M | 988 K | -2.02 M | 324 K | 1.19 M | 6.18 M | 21.9 M | 34.7 M | 58.6 M | -399 K | -10.3 K | - |
EBITDA per Share |
-4.31 | -3.29 | -0.25 | -0.22 | -0.18 | -1.75 | -2.03 | -2.74 | -7.24 | -36.6 | -79.1 | -87.8 | -120 | -71.4 | - | - | - |
EV/EBITDA |
-0.4 | 0.7 | -5.4 | 0.7 | 6.5 | 1.0 | 0.0 | 0.4 | 0.1 | -0.0 | -0.3 | -1.7 | -3.2 | -11.5 | - | - | - |
PEG |
-0.01 | -0.01 | 0.45 | 0.09 | 0.14 | -0.09 | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 | -0.15 | 0.05 | 1.46 | - | - | - |
P/B |
1.2 | 0.6 | 2.8 | 0.7 | 1.2 | 0.8 | 0.9 | 0.6 | 0.9 | 1.0 | 2.0 | 3.0 | 3.7 | 11.3 | - | - | - |
P/CF |
-1.6 | -2.2 | -12.0 | -4.1 | -9.7 | -1.9 | -1.3 | -0.6 | -1.0 | -0.6 | -0.5 | -2.6 | -4.3 | -14.5 | - | - | - |
ROE % |
-88.35 | -35.68 | -33.06 | -22.85 | -14.92 | -65.62 | -131.04 | -129.53 | -117.06 | -205.64 | -421.20 | -154.32 | -101.73 | -98.15 | - | 127.60 | -387.77 |
ROA % |
-73.03 | -33.36 | -31.27 | -21.82 | -14.59 | -41.62 | -118.98 | -97.31 | -99.49 | -153.68 | -252.43 | -124.60 | -89.80 | -74.42 | - | - | - |
ROCE % |
-94.38 | -38.64 | -34.47 | -23.47 | -14.86 | -65.62 | -131.13 | -129.86 | -103.59 | -234.08 | -340.98 | -128.69 | -101.73 | -97.94 | - | - | - |
Current Ratio |
5.8 | 15.4 | 18.4 | 22.2 | 45.2 | 2.7 | 10.8 | 4.0 | 6.4 | 3.1 | 1.7 | 4.1 | 5.3 | 1.2 | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | 206.8 | 80.2 | 107.3 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | 42.6 | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | 2245.1 | 636.8 | 7.1 | 379.4 | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | 249.4 | 80.2 | 107.3 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | -2245.1 | -387.4 | 73.2 | -272.1 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Atossa Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.95 | -1.11 | -0.07 | -0.07 | -0.05 | - | -0.06 | -0.05 | -0.05 | - | -0.05 | -0.08 | -0.05 | - | -0.06 | -0.05 | -0.04 | - | -0.04 | -0.06 | -0.04 | - | -0.34 | -0.43 | -0.32 | - | -0.36 | -0.8 | -0.62 | - | -0.64 | -5.08 | -8.48 | - | -2.11 | -7.72 | -5.4 | - | 0.07 | -0.67 | -0.98 | - | -0.15 | -0.11 | -0.13 | - | -0.13 | -0.13 | -0.1 | - | -0.22 | -0.17 | -0.14 | - | -0.1 | -0.1 | -0.09 | - | -0.11 | - | - |
EBITDA per Share |
-0.98 | -1.14 | - | - | -0.06 | - | - | - | -0.06 | - | - | - | -0.06 | - | -0.06 | -0.05 | -0.04 | - | -0.04 | -0.06 | -0.04 | - | -0.34 | -0.43 | -0.32 | - | -0.36 | -0.8 | -0.62 | - | -0.63 | -1.34 | -8.45 | - | -1.89 | -2.93 | -5.27 | - | -0.44 | -0.61 | -0.95 | - | -1.99 | -0.11 | -0.13 | - | -0.12 | -0.12 | -0.09 | - | -0.2 | -0.16 | -0.14 | - | -0.1 | -0.1 | -0.09 | - | -0.11 | - | - |
ROE % |
-95.16 | -73.80 | -52.15 | -42.24 | -34.50 | -24.21 | -30.55 | -30.11 | -28.11 | -21.26 | -27.73 | -26.51 | -20.68 | -15.13 | -18.81 | -17.23 | -14.64 | -11.10 | -23.95 | -34.65 | -40.61 | -38.08 | -63.05 | -105.41 | -121.99 | -111.14 | -148.73 | -170.80 | -136.89 | -105.93 | -137.41 | -132.12 | -201.81 | -180.52 | -173.92 | -198.04 | -240.89 | -124.16 | -239.56 | -330.23 | -363.75 | -288.60 | -322.77 | -240.93 | -182.26 | -93.12 | -126.15 | -116.36 | -101.10 | -75.71 | -97.81 | -87.34 | -83.51 | -65.20 | -146.79 | -22.57 | -20.54 | - | -81.60 | - | - |
ROA % |
-79.61 | -62.81 | -46.63 | -38.69 | -32.09 | -22.60 | -28.72 | -28.70 | -27.06 | -20.60 | -26.92 | -25.78 | -20.18 | -14.78 | -18.41 | -16.92 | -14.45 | -10.97 | -19.12 | -24.60 | -26.66 | -24.15 | -46.82 | -88.80 | -107.79 | -100.91 | -129.15 | -141.82 | -107.69 | -79.58 | -106.33 | -105.55 | -169.42 | -153.43 | -148.49 | -163.29 | -192.00 | -92.78 | -161.95 | -217.26 | -229.13 | -172.96 | -200.55 | -158.49 | -128.61 | -75.19 | -104.35 | -98.27 | -87.34 | -66.84 | -83.59 | -71.54 | -65.60 | -49.43 | -90.86 | -17.11 | -15.57 | - | -41.43 | - | - |
ROCE % |
-99.03 | -77.98 | -54.27 | -44.55 | -37.02 | -25.67 | -33.27 | -32.03 | -29.44 | -21.30 | -27.92 | -25.39 | -21.47 | -15.20 | -18.85 | -17.09 | -14.55 | -11.04 | -23.95 | -34.79 | -40.74 | -38.21 | -63.28 | -105.75 | -122.16 | -111.35 | -148.94 | -170.92 | -136.82 | -105.93 | -135.56 | -125.30 | -102.80 | -81.51 | -131.83 | -157.81 | -205.64 | -181.08 | -283.78 | -318.20 | -350.05 | -274.90 | -309.06 | -239.92 | -180.56 | -93.10 | -126.13 | -116.33 | -101.09 | -75.71 | -97.65 | -87.15 | -83.30 | -64.99 | -146.68 | -22.53 | -20.52 | - | -81.69 | - | - |
Current Ratio |
5.9 | 5.1 | 7.0 | 9.5 | 13.0 | 15.4 | 13.7 | 15.1 | 17.1 | 18.4 | 29.5 | 31.1 | 39.5 | 22.2 | 44.2 | 35.4 | 59.2 | 45.2 | 85.3 | - | - | 2.7 | 2.7 | 23.4 | 46.8 | 10.9 | 10.9 | 10.9 | 10.9 | 4.0 | 4.0 | 4.0 | 4.0 | - | - | - | - | 4.0 | - | - | - | 2.5 | 1.9 | 1.8 | 1.8 | 5.2 | 5.2 | 5.2 | 5.2 | 8.5 | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4356.2 | 2753.3 | 826.5 | - | 165.7 | 38.9 | 70.1 | - | 122.4 | 57.9 | 119.2 | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.1 | - | - | - | - | - | - | - | 873.0 | 52.9 | 53.4 | - | 691.6 | 349.9 | 1897.8 | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.6 | - | - | - | 4356.2 | 2753.3 | 826.5 | - | 165.7 | 38.9 | 70.1 | - | 122.4 | 57.9 | 119.2 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -197.5 | - | - | - | 4356.2 | 2753.3 | 826.5 | - | -707.3 | -14.0 | 16.7 | - | -569.2 | -292.0 | -1778.7 | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Atossa Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Singapore
USA
Canada
Israel
Britain
China
Irlanda
Schweiz
Germany
